Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Given the central role of p53, Myc, and MCL1 in cancer progression ... proteins of interest and have clinically relevant substrate degradation profiles offering broad therapeutic opportunities.

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

"Because Aurora-A stabilizes N-Myc against degradation, inhibiting the interaction could represent a promising approach for anticancer drug development and our finding that peptidomimetics can ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

This review highlights the critical role of ubiquitination in governing the functionality of cancer stem cells (CSCs), shedding light on potential therapeutic targets for combating tumor progression, ...